Human versus non-human sex steroid use in hormone replacement therapies part 1: Preclinical data.

Abstract Prior to 2002, hormone replacement therapy (HRT) was considered to be an important component of postmenopausal healthcare. This was based on a plethora of basic, epidemiological and clinical studies demonstrating the health benefits of supplementation with human sex steroids. However, adverse findings from the Women's Health Initiative (WHI) studies that examined the 2 major forms of HRT in use in the US at that time - Premarin (conjugated equine estrogens; CEE) and Prempro (CEE + medroxyprogesterone acetate; MPA), cast a shadow over the use of any form of HRT. Here we review the biochemical and physiological differences between the non-human WHI study hormones – CEE and MPA, and their respective human counterparts 17β-estradiol (E 2) and progesterone (P 4). Preclinical data from the last 30 years demonstrate clear differences between human and non-human sex steroids on numerous molecular, physiological and functional parameters in brain, heart and reproductive tissue. In contrast to CEE supplementation, which is not always detrimental although certainly not as optimal as E 2 supplementation, MPA is clearly not equivalent to P 4 , having detrimental effects on cognitive, cardiac and reproductive function. Moreover, unlike P 4 , MPA is clearly antagonistic of the positive effects of E 2 and CEE on tissue function. These data indicate that minor chemical changes to human sex steroids result in physiologically distinct actions that are not optimal for tissue health and functioning. Highlights • Post-menopausal hormone replacement therapy is currently not recommended. • This recommendation is based on negative findings with the hormone replacement therapies Premarin (CEE) & Prempro (CEE+MPA). • Data indicates functional differences between non-human steroids in Premarin & Prempro compared to human sex steroids. • Preclinical data demonstrate CEE and MPA are not optimal or detrimental when compared with 17β-estradiol and progesterone. • Preclinical data indicates MPA in particular, and perhaps CEE, should be avoided for post-menopausal hormone therapy. [ABSTRACT FROM AUTHOR]